Last Updated: September 24, 2026

GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE Drug Patent Profile

✉ Email this page to a colleague

« Back to Dashboard

When do Guaifenesin And Dextromethorphan Hydrobromide patents expire, and when can generic versions of Guaifenesin And Dextromethorphan Hydrobromide launch?

Guaifenesin And Dextromethorphan Hydrobromide is a drug marketed by Actavis Labs Fl, Amneal Pharms, Aurobindo Pharma, Dr Reddys, Perrigo R And D, and Sun Pharm. and is included in six NDAs.

The generic ingredient in GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE is dextromethorphan hydrobromide; guaifenesin. There is one drug master file entry for this compound. Sixty-two suppliers are listed for this compound. Additional details are available on the dextromethorphan hydrobromide; guaifenesin profile page.

AI Deep Research

Questions you can ask:

What is the 5 year forecast for GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE?
What are the global sales for GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE?
What is Average Wholesale Price for GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE?

Summary for GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE

US Patents:	0
Applicants:	6
NDAs:	6
Finished Product Suppliers / Packagers:	58
Raw Ingredient (Bulk) Api Vendors:	3
Patent Applications:	20
What excipients (inactive ingredients) are in GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE?	GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE excipients list
DailyMed Link:	GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE at DailyMed

Drug patent expirations by year for GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE

Pharmacology for GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE

Drug Class	Expectorant Sigma-1 Agonist Uncompetitive N-methyl-D-aspartate Receptor Antagonist
Mechanism of Action	Sigma-1 Receptor Agonists Uncompetitive NMDA Receptor Antagonists
Physiological Effect	Decreased Respiratory Secretion Viscosity Increased Respiratory Secretions

US Patents and Regulatory Information for GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Actavis Labs Fl	GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE	dextromethorphan hydrobromide; guaifenesin	TABLET, EXTENDED RELEASE;ORAL	091070-001	Aug 31, 2015		OTC	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Dr Reddys	GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE	dextromethorphan hydrobromide; guaifenesin	TABLET, EXTENDED RELEASE;ORAL	217340-001	Aug 1, 2023		OTC	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Amneal Pharms	GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE	dextromethorphan hydrobromide; guaifenesin	TABLET, EXTENDED RELEASE;ORAL	209692-002	Nov 1, 2018		OTC	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Sun Pharm	GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE	dextromethorphan hydrobromide; guaifenesin	TABLET, EXTENDED RELEASE;ORAL	214781-002	Jul 1, 2021		OTC	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Dr Reddys	GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE	dextromethorphan hydrobromide; guaifenesin	TABLET, EXTENDED RELEASE;ORAL	217340-002	Aug 1, 2023		OTC	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Actavis Labs Fl	GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE	dextromethorphan hydrobromide; guaifenesin	TABLET, EXTENDED RELEASE;ORAL	091070-002	Aug 31, 2015		OTC	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.